| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50242-0108-86 | 50242-0108 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | Jun 23, 2017 | In Use | |
| 50242-0159-01 | 50242-0159 | Mosunetuzumab | Lunsumio | 1.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Dec 22, 2022 | In Use | |
| 61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 00173-0808-02 | 00173-0808 | Ofatumumab | Arzerra | Immunotherapy | Monoclonal Antibody | CD20 | Oct 26, 2009 | Mar 31, 2012 | No Longer Used | ||
| 69448-0021-63 | 69448-0021 | Denosumab-desu | OSVYRTI | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 6, 2026 | In Use | |
| 57894-0421-01 | 57894-0421 | Siltuximab | Sylvant | 400.0 mg/1 | Immunotherapy | Monoclonal Antibody | Interleukin-6 Antagonists | Intravenous | Apr 1, 2014 | Jan 31, 2021 | No Longer Used |
| 83257-0001-11 | 83257-0001 | Trastuzumab-dkst | OGIVRI | 150.0 mg/7.4mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
| 00002-8926-01 | 00002-8926 | Olaratumab | Lartruvo | 10.0 mg/mL | Immunotherapy | Monoclonal Antibody | PDGFR | Intravenous | Oct 19, 2016 | Nov 27, 2020 | No Longer Used |
| 58468-0357-03 | 58468-0357 | Alemtuzumab | Campath | 30.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD52 | Intravenous | Nov 30, 2009 | In Use | |
| 82143-0002-01 | 82143-0002 | Bevacizumab-tnjn | Avzivi | 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jan 1, 2025 | In Use | |
| 50242-0070-01 | 50242-0070 | Obinutuzumab | Gazyva | 1000.0 mg/40mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Nov 1, 2013 | In Use | |
| 83257-0003-01 | 83257-0003 | Trastuzumab-dkst, Trastuzumab | OGIVRI | 420.0 mg/20mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 1, 2023 | In Use | |
| 00143-9165-01 | 00143-9165 | Denosumab-qbde | ENOBY | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Jan 8, 2026 | In Use | |
| 50242-0177-01 | 50242-0177 | Mosunetuzumab | Lunsumio Velo | 5.0 mg/.5mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | Dec 19, 2025 | In Use | |
| 00002-7716-01 | 00002-7716 | Necitumumab | Portrazza | 16.0 mg/mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Nov 24, 2015 | May 27, 2026 | No Longer Used |
| 00024-0674-01 | 00024-0674 | Isatuximab-irfc | Sarclisa Escena | 140.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD38 | Subcutaneous | Jul 9, 2026 | In Use | |
| 83457-0012-10 | 83457-0012 | Denosumab | OSPOMYV | 60.0 mg/mL | Ancillary Therapy | Monoclonal Antibody | RANKL | Subcutaneous | Oct 10, 2025 | In Use | |
| 55513-0164-01 | 55513-0164 | Traztuzumab-anns, trastuzumab-anns | Kanjinti | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Feb 1, 2023 | Jun 30, 2025 | No Longer Used | |
| 72606-0038-01 | 72606-0038 | Denosumab-bmwo | Osenvelt | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jul 2, 2025 | In Use | |
| 57894-0450-01 | 57894-0450 | Teclistamab-cqyv | TECVAYLI | 90.0 mg/mL | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | Subcutaneous | Oct 25, 2022 | In Use | |
| 50242-0201-01 | 50242-0201 | Mosunetuzumab | Lunsumio Velo | 45.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Subcutaneous | Dec 19, 2025 | In Use | |
| 57894-0502-20 | 57894-0502 | Daratumumab | Darzalex | 100.0 mg/5mL | Immunotherapy | Monoclonal Antibody | CD38 | Intravenous | Nov 16, 2015 | Nov 30, 2024 | In Use |
| 83257-0004-12 | 83257-0004 | Trastuzumab-dkst | OGIVRI | Immunotherapy | Monoclonal Antibody | HER2 | Oct 1, 2023 | In Use | |||
| 55513-0956-01 | 55513-0956 | Panitumumab | Vectibix | 400.0 mg/20mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | In Use | |
| 55513-0955-01 | 55513-0955 | Panitumumab | Vectibix | 200.0 mg/10mL | Immunotherapy | Monoclonal Antibody | EGFR | Intravenous | Oct 10, 2006 | Feb 28, 2010 | No Longer Used |
Found 12611 results — Export these results
Home